Manufacturing, Packaging & Detailing Market Research Reports & Industry Analysis
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA. The cGMPs provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
Manufacturing, Packaging & Detailing Industry Research & Market Reports
-
Biotechnology / Pharmaceutical Services Outsourcing
... Billion by 2030, growing at a CAGR of 5.5% over the analysis period 2024-2030. Consulting Services, one of the segments analyzed in the report, is expected to record a 5.4% CAGR and reach US$20.9 Billion ... Read More
-
Triacetin
... 4.3% over the analysis period 2024-2030. Plasticizer, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$193.2 Million by the end of the analysis period. Growth in ... Read More
-
Sterility Testing
... CAGR of 10.9% over the analysis period 2024-2030. Kits & Reagents, one of the segments analyzed in the report, is expected to record a 12.2% CAGR and reach US$184.9 Million by the end of the ... Read More
-
Sanitary Valves
... CAGR of 3.4% over the analysis period 2024-2030. Control Valves, one of the segments analyzed in the report, is expected to record a 3.9% CAGR and reach US$223.4 Million by the end of the analysis ... Read More
-
Pharmaceutical Glass Packaging
... at a CAGR of 7.6% over the analysis period 2024-2030. Bottles, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$10.5 Billion by the end of the ... Read More
-
Pharmaceutical Grade Sodium Chloride
... 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Dialysis, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$417.5 Million by the end ... Read More
-
Pharmaceutical Excipients
... CAGR of 4.5% over the analysis period 2024-2030. Organic Chemicals, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$9.8 Billion by the end of the analysis ... Read More
-
Isosorbide
... 7.4% over the analysis period 2024-2030. PEIT, one of the segments analyzed in the report, is expected to record a 9.1% CAGR and reach US$439.5 Million by the end of the analysis period. Growth in ... Read More
-
Ginseng
... 10.2% over the analysis period 2024-2030. Asian Ginseng, one of the segments analyzed in the report, is expected to record a 10.0% CAGR and reach US$11.2 Billion by the end of the analysis period. Growth ... Read More
-
Empty Capsules
... CAGR of 5.5% over the analysis period 2024-2030. Gelatin, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$3.5 Billion by the end of the analysis period. ... Read More
-
Efficacy Testing
... CAGR of 10.4% over the analysis period 2024-2030. Consumables, one of the segments analyzed in the report, is expected to record a 11.1% CAGR and reach US$713.2 Million by the end of the analysis period. ... Read More
-
Chronic Kidney Disease (CKD) Drugs
... Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antihypertensives, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$6.0 Billion by ... Read More
-
Chemotherapy-induced Nausea and Vomiting Drugs
... Billion by 2030, growing at a CAGR of 5.1% over the analysis period 2024-2030. Serotonin Receptor Antagonist, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$2.0 ... Read More
-
Contract Packaging
... CAGR of 8.7% over the analysis period 2024-2030. Food & Beverage, one of the segments analyzed in the report, is expected to record a 8.7% CAGR and reach US$55.4 Billion by the end of the ... Read More
-
Alpha-1 Antitrypsin Drugs
... at a CAGR of 9.6% over the analysis period 2024-2030. Prolastin C, one of the segments analyzed in the report, is expected to record a 9.4% CAGR and reach US$2.1 Billion by the end of ... Read More
-
Bulk Paclitaxel
... CAGR of 8.5% over the analysis period 2024-2030. Semi-Synthetic Paclitaxel API, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$139.1 Million by the end of the ... Read More
-
Human Growth Hormone Drugs
... 2030, growing at a CAGR of 4.2% over the analysis period 2024-2030. Subcutaneous, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$3.4 Billion by the end ... Read More
-
Antibacterial Drugs
... CAGR of 3.8% over the analysis period 2024-2030. ß-lactams, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$35.4 Billion by the end of the analysis period. ... Read More
-
Oral Solid Dosage Pharmaceutical Formulation
... Million by 2030, growing at a CAGR of 3.4% over the analysis period 2024-2030. Tablets, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$280.1 Million by ... Read More
-
Global N-Acetyl-L-Cysteine Market Research Report 2025
... N-Acetyl-L-Cysteine was increase from $ 65.64 million in 2024 to reach $ 107.24 million by 2031, at a CAGR of 7.87% during the forecast period of 2025 through 2031. China market for N-Acetyl-L-Cysteine was increase ... Read More
-
Global L-Creatine Market Research Report 2025
... L-Creatine was increase from $ 237.38 million in 2024 to reach $289.67 million by 2031, at a CAGR of 2.36% during the forecast period of 2025 through 2031. China market for L-Creatine is estimated to ... Read More
-
Global Seamless Capsule Market Report, History and Forecast 2020-2031
... report aims to provide a comprehensive presentation of the global market for Seamless Capsule, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in ... Read More
-
Sarcoma Drugs
... CAGR of 7.6% over the analysis period 2024-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$1.9 Billion by the end of the analysis ... Read More
-
Myeloproliferative Disorders Drugs
... at a CAGR of 4.3% over the analysis period 2024-2030. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is expected to record a 3.7% CAGR and reach US$9.2 Billion by ... Read More
-
Healthcare Distribution
... CAGR of 13.5% over the analysis period 2024-2030. Pharmaceutical, one of the segments analyzed in the report, is expected to record a 13.3% CAGR and reach US$2.3 Trillion by the end of the analysis period. ... Read More
Research Assistance
